Programme Thesis
The DayOne Accelerator funds early-stage tech startups that address challenges in pharma R&D, providing mentorship, industry access, and a structured program to accelerate their development. It exists to bridge the gap between innovative healthtech/techbio solutions and the pharmaceutical industry, fostering collaborations that can transform drug discovery and development.
Selection Criteria
- Early-stage startup (pre-seed/seed) with a working prototype or proof-of-concept.
- Focus on healthtech or techbio, specifically developing tech solutions to enable Pharma R&D (no molecules).
- Clear value proposition for pharma R&D (e.g., improving efficiency, reducing costs, addressing unmet needs).
- Strong team with relevant expertise and commitment.
- Potential for scalability and impact within the pharma ecosystem.
- Willingness to engage with the DayOne network and participate in the accelerator program.
Past Winners / Cohort Profiles
The page does not list specific past winners, but DayOne Accelerator typically selects startups that are developing software, AI/ML tools, or platforms that address pharma R&D bottlenecks. Past cohorts have included startups in areas like clinical trial optimization, drug discovery AI, patient recruitment, and real-world data analytics. The archetype is a technical founder with deep domain knowledge, a validated MVP, and a clear path to pilot with pharma partners.
Ideal Candidate Fingerprint
The ideal applicant is a pre-seed startup with a validated proof-of-concept that directly addresses a specific pain point in pharma R&D, such as drug resistance prediction, target identification, or clinical trial design. The team should combine technical expertise (e.g., AI/ML, bioinformatics) with a clear understanding of pharma workflows, and be ready to leverage DayOne's network to secure pilots and partnerships.
Recommended Framing
For Eniola, the strongest angle is to frame TOPOLOGIX as the core venture for this accelerator, given its direct relevance to pharma R&D (predicting drug resistance mutations) and its validated proof-of-concept (AUROC 0.804 on Platinum benchmark, outperforming structure-based tools). The framing should emphasize how TOPOLOGIX's sequence-based approach overcomes the limitations of structure-based methods, offering a scalable, high-coverage solution that pharma companies can integrate into their drug development pipelines, and highlight Eniola's unique blend of pharmacological and computational expertise as a founder.
Watch Out
The program is for startups, and Eniola is an independent researcher; the venture may need to be positioned as a startup with a clear commercial path. Also, the program is based in Switzerland, but international startups are eligible; however, the application may require a commitment to relocate or engage with the Swiss ecosystem. The deadline is May 31, 2026, so timing is feasible.
Research History
2026-08-04 20:00 · medium confidence
2026-07-30 09:07 · medium confidence